Sign in
4

Changes in Ownership

Monopar Therapeutics Filed Acc 0001437749-26-031411

Chief Executive Officer sold 29,056 shares at an average $88.00 ($2,556,851)

  • Chief Executive Officer acquired 29,056 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Robinson Chandler · Chief Executive Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-09-24 Exercise or conversion : show line 1 in the form 10b5-1 +14,056 $30.00 $421,680 113,323 D
2026-09-24 Exercise or conversion : show line 2 in the form 10b5-1 +15,000 $14.00 $210,000 128,323 D
2026-09-24 Sale : show line 3 in the form 10b5-1 −10,450 $87.15 $910,718 117,873 D
2026-09-24 Sale : show line 4 in the form 10b5-1 −9,638 $87.96 $847,758 108,235 D
2026-09-24 Sale : show line 5 in the form 10b5-1 −8,368 $88.97 $744,501 99,867 D
2026-09-24 Sale : show line 6 in the form 10b5-1 −600 $89.79 $53,874 99,267 D
Open-market sales · 29,056 sh · avg $88.00 · $2,556,851

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-09-24 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option −14,056 15,044 D
2026-09-24 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option −15,000 27,204 D
Loading xslF345X06/rdgdoc.xml…